AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Reporting cash rewards on your taxes can be confusing. Find out what you need to know to ensure you report correctly and avoid issues.
21,129 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Tech weakness and memory-chip swings are weighing on major indexes this June. Learn what’s driving the move and how t...
As July opens, a low-cost dividend ETF stands out for a $2,000 allocation. This report breaks down why it’s considere...
Hexcel and Rocket Lab USA sit on opposite ends of the aerospace spectrum. One anchors aircraft efficiency; the other ...
A small tech firm is rethinking its core business, moving from crypto mining to powering AI clouds. This growth phase...
Two AI-driven stocks with durable moats and solid cash flow could deliver outperformance over the next five years. Ex...
DVY’s 3.3% yield looks weak when set against a 4.55% 10-year Treasury, underscoring a shifting landscape for income-f...
A little-known dividend-focused ETF has boosted its quarterly payout 38% over three years, delivering steady income i...
Investors are rechecking fintech momentum as the stock market today, feb. delivers a choppy session. This guide break...
Zscaler posted a strong quarter, beating revenue and EPS estimates while signaling durable ARR growth. Here are the n...
Investors are eyeing hydrogen leaders as Plug Power remains in the spotlight. This piece breaks down why plug power s...
Intel remains the Dow's most shorted stock as fresh data show rising short interest amid continued cash burn in the f...